Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05291169 · ClinicalTrials.gov registry record · NA

Omeza Combination Therapy With Standard of Care to Standard of Care Alone for Chronic Venous Leg Ulcers

A NA study of Venous Leg Ulcer, sponsored by Omeza.

Completed
Registry status
NA
Development phase
54
Enrollment target
7
Study locations

NCT05291169 is a NA study of Venous Leg Ulcer that has completed, run by Omeza. The registered enrollment target is 54 participants, below the 243-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target (78% lower). The trial reports 7 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05291169, a NA study of Venous Leg Ulcer, has completed, sponsored by Omeza.

COMPLETED
Registry status
NA
Development phase
54 participants
Enrollment target
7
Study locations

Study Summary

A Randomized, Multicenter, Open Label Study Comparing Omeza Combination Therapy with Standard of Care to Standard of Care alone for Chronic Venous Leg Ulcers over the course of 4 weeks

Conditions Studied

Interventions

  • DEVICE Omeza® OCM™

Study Locations (7)

Pennsylvania

  • The Foot and Ankle Wellness Center of Western Pennsylvania - Ford City
  • ACMH Wound Clinic - Kittanning
  • Serena Group - Monroeville

Florida

  • Royal Research, Corp - Hollywood
  • Three Rivers Wound and Hyperbaric Center - North Port

California

  • New Hope Podiatry - Los Angeles

Oklahoma

  • Wound Care of Tulsa - Tulsa

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2022-04-11
Est. Completion 2024-03-01
Phase NA

Sponsor

Omeza

6 total trials

What the Registry Record Tells You About NCT05291169

The ClinicalTrials.gov registry entry for NCT05291169 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target (78% lower). The listed sponsor is Omeza, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Venous Leg Ulcer appearing as the primary indexed condition, and to 1 intervention - of which Omeza® OCM™ is the first listed.

NCT05291169 reports 7 study locations spanning 4 distinct geographic areas - top geographies include Pennsylvania, Florida, California.

Frequently Asked Questions

What is clinical trial NCT05291169 about?

NCT05291169 is a clinical study titled "Omeza Combination Therapy With Standard of Care to Standard of Care Alone for Chronic Venous Leg Ulcers". A Randomized, Multicenter, Open Label Study Comparing Omeza Combination Therapy with Standard of Care to Standard of Care alone for Chronic Venous Leg Ulcers over the course of 4 weeks

What is the current status of trial NCT05291169?

This trial is currently completed. It is a NA study. The enrollment target is 54 participants. The study started on 2022-04-11. Estimated completion is 2024-03-01.

What conditions does trial NCT05291169 study?

This clinical trial studies the following conditions: Venous Leg Ulcer.

What interventions are being tested in trial NCT05291169?

The interventions under investigation include: Omeza® OCM™ (DEVICE).

Who is sponsoring clinical trial NCT05291169?

This trial is sponsored by Omeza, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05291169 being conducted?

This trial has 7 study locations across California, Florida, Oklahoma, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Venous Leg Ulcer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.